Second Sight Medical Products (EYES) and IRIDEX (IRIX) Head-To-Head Analysis

Second Sight Medical Products (NASDAQ: EYES) and IRIDEX (NASDAQ:IRIX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability.

Risk and Volatility

Second Sight Medical Products has a beta of 3.15, meaning that its stock price is 215% more volatile than the S&P 500. Comparatively, IRIDEX has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500.

Insider and Institutional Ownership

10.7% of Second Sight Medical Products shares are owned by institutional investors. Comparatively, 48.8% of IRIDEX shares are owned by institutional investors. 34.7% of Second Sight Medical Products shares are owned by company insiders. Comparatively, 4.8% of IRIDEX shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Second Sight Medical Products and IRIDEX’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Second Sight Medical Products -387.35% -307.76% -194.77%
IRIDEX -35.95% -44.78% -34.72%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Second Sight Medical Products and IRIDEX, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Second Sight Medical Products 0 0 1 0 3.00
IRIDEX 0 0 1 0 3.00

Second Sight Medical Products currently has a consensus target price of $5.00, indicating a potential upside of 194.12%. IRIDEX has a consensus target price of $13.00, indicating a potential upside of 108.00%. Given Second Sight Medical Products’ higher probable upside, equities analysts clearly believe Second Sight Medical Products is more favorable than IRIDEX.

Valuation & Earnings

This table compares Second Sight Medical Products and IRIDEX’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Second Sight Medical Products $7.96 million 14.23 -$28.51 million ($0.59) -2.88
IRIDEX $41.59 million 1.75 -$12.86 million ($1.11) -5.63

IRIDEX has higher revenue and earnings than Second Sight Medical Products. IRIDEX is trading at a lower price-to-earnings ratio than Second Sight Medical Products, indicating that it is currently the more affordable of the two stocks.

Second Sight Medical Products Company Profile

Second Sight Medical Products, Inc., together with its subsidiaries, develops, manufactures, and markets prosthetic devices to restore functional vision of blind individuals in the United States, Canada, Europe, the Middle East, and Asia. It offers Argus II System, which treats outer retinal degenerations, such as retinitis pigmentosa. The company was formerly known as Second Sight LLC. and changed its name to Second Sight Medical Products, Inc. Second Sight Medical Products, Inc. was founded in 1998 and is headquartered in Sylmar, California.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. It also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures. In addition, the company offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system that delivers laser to treat glaucoma; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe Illuminate and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products used in vitrectomy procedures. It serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. IRIDEX Corporation markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was founded in 1989 and is headquartered in Mountain View, California.

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply